Premium
Transient prehypertensive treatment in spontaneously hypertensive rats: effects of anti‐inflammatory therapy
Author(s) -
Heijnen Bart,
Essen Helma,
Janssen Ben,
StruijkerBoudier Harry
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.1030.9
Subject(s) - prehypertension , medicine , losartan , blood pressure , endocrinology , renin–angiotensin system , inflammation
Transient administration of inhibitors of the renin angiotensin system during the prehypertensive period of spontaneously hypertensive rats (SHR) leads to a long‐lasting lowering of blood pressure (BP) and a reduction of end organ damage. Renal inflammation plays a pivotal role in the maintenance of hypertension and is also believed to have a causal role in the onset of high BP development. To test the latter hypothesis we studied if transient prehypertensive treatment with anti‐inflammatory agents would affect BP in SHR. Male SHR were treated between 4–8 weeks of age with either PDTC (P, specific NFkB inhibitor: 200 mg/kg/day via drinking water), Quercetin (Q, an antioxidant: 1% via the diet), or Losartan (L, 20 mg/kg/day via s.c. implanted osmotic minipumps). Untreated SHR served as controls. BP was determined intra‐arterially at 8 and 12 weeks of age In comparison to untreated SHR, BP was significantly reduced by treatment with Q and L, but not with P, at 8 weeks of age. At 12 weeks of age, i.e. 4 weeks after treatment was stopped, a significant reduction in BP was still observed in L treated rats only. No BP differences were present between P or Q treated and control rats. These data show that transient anti‐inflammatory treatment during the prehypertensive phase does not reduce BP for a sustained period in the SHR. This research was performed within the framework of TI‐Pharma: project T2‐301